New role of ID3 in melanoma adaptive drug-resistance

Adaptive resistance to targeted therapy such as BRAF inhibitors represents in melanoma a major drawback to this otherwise powerful treatment. Some of the underlying molecular mechanisms have recently been described: hyperactivation of the BRAF-MAPK pathway, of the AKT pathway, of the TGFβ/EGFR/PDGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachindra, Larribère, Lionel, Novak, Daniel, Wu, Huizi, Hüser, Laura, Granados, Karol, Orouji, Elias, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746373/
https://www.ncbi.nlm.nih.gov/pubmed/29299138
http://dx.doi.org/10.18632/oncotarget.22698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746373/
https://www.ncbi.nlm.nih.gov/pubmed/29299138
http://dx.doi.org/10.18632/oncotarget.22698

Ejemplares similares